Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Good efficacy for challenging disease + improved QoL in pall setting. #lymsm
www.asco.org/abstracts-pr...
The latest findings from our ongoing BISON-PRO Quality of Life Study (bison-pro.org): measuring financial toxicity in patients with lymphoma & CLL from active surveillance through treatment and survivorship. Manuscripts forthcoming! #lymsm cc @cuhematology.bsky.social
bison-pro.org/new-bison-pr...
Supports Hans IHC as a practical & reliable procedure for COO classification in DLBCL. Particularly important with pola non-GC data. #lymsm
Frontline H. pylori eradication for extragastric ENMZL #lymsm
- 26 pts, 46% conjunctival, 19% parotid
- ORR 65% (CR 39%, PR 27%), time to CR 6 mos
- 7-yr EFS 77%, OS 96%
- HP+ dx with better responses (obv), t(11;18) less responses
Provocative evidence re: HP+ in non-gastric sites...
...but 4 Gy RT is nontoxic with robust local dx control.
www.nature.com/articles/s41... #lymsm #medsky
- If CR: 1-yr PFS 76%, 1-yr OS 77%
- CRS 33% (G3+ 4.6%), ICANS 13% (G3+ 0.6%)
- ICU admission 17%!
RW outcomes inferior to trial results, mostly due to high-risk disease & trial-ineligible patients. However, CRs can be durable; need to identify predictors of response. #lymsm
Hans IHC vs GEP for DLBCL COO classification #EHA2026
Large meta-analysis (19 studies, 2247 tumors) to eval noninferiority of Hans IHC to GEP.
Estimated accuracy:
- Hans IHC 90%
- pooled GEP 95%
- 4.5% difference met noninferiority margin
- sens 6.5% / NPV 6.4%
library.ehaweb.org/eha/2026/eha...
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Ajay Major, MD, MBA
Blood Cancer Journal - Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma
